Tuğrul Elverdi

Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion

Ahmet Emre Eşkazan, Deniz Eyice Karabacak, Enes Ali Kurt et al. · Leukemia Research · 2014 · 34 citations

Hematological Malignancy, Oncology, Mixed-phenotype Acute Leukemia +9

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey

Ayşe Salihoğlu, Tuğrul Elverdi, Ìhsan Karadoǧan et al. · Annals of Hematology · 2014 · 33 citations · Full text

Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec

Ahmet Emre Eşkazan, Sevil Sadri, Dilek Keskin et al. · Clinical Lymphoma Myeloma & Leukemia · 2017 · 25 citations

Hematological Malignancy, Early Molecular Response, Oncology +10

The role of 68Ga-DOTA-TATE PET/CT scanning in the evaluation of patients with multiple myeloma

Kerim Sönmezoğlu, Betül Vatankulu, Tuğrul Elverdi et al. · Nuclear Medicine Communications · 2016 · 19 citations · Full text

Brentuximab vedotin consolidation therapy after autologous stem‐cell transplantation in patients with high‐risk Hodgkin lymphoma: Multicenter retrospective study

Olga Meltem Akay, Murat Özbalak, Mustafa Pehlıvan et al. · Hematological Oncology · 2021 · 19 citations